Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer
10.3971/j.issn.1000-8578.2024.23.0909
- VernacularTitle:赛沃替尼在Ⅲ/Ⅳ期非小细胞肺癌中的疗效观察
- Author:
Cheng ZHONG
1
;
Yang ZHANG
;
Ziang CHU
;
Hong QIAN
Author Information
1. Navy Anqing Hospital Cancer Center, Anqing 246004, China
- Publication Type:Research Article
- Keywords:
Non-small cell lung cancer;
Mesenchymal-epithelial transition factor;
Savolitinib
- From:
Cancer Research on Prevention and Treatment
2024;51(3):191-194
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC). Methods A total of 95 patients with MET 14 exon (METex14) jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group (47 cases) and an observation group (48 cases) through a random-number table method. The patients in the control group were treated with crizotinib, whereas those in the observation group were treated with savolitinib. The clinical efficacy and incidence of toxic side effects in both groups were evaluated through a chi-square test, and survival was evaluated through Kaplan-Meier survival analysis. Results Compared with control group (31.91% and 70.21%), the objective response rate and disease control rate of the observation group were 52.08% and 87.50%, respectively (P<0.05). According to Kaplan-Meier survival analysis, the overall survival and progression free survival rates in the observation group were higher than those in the control group (Log rank χ2=8.003, 4.528; P=0.005, 0.033). No statistically significant difference in the degree of toxic side effects was found between the groups (P>0.05). Conclusion Savolitinib can improve the efficacy of treatment for stage Ⅲ/Ⅳ METex14 skip mutation NSCLC patients, prolong survival, enhance the tolerance of patients to savolitinib, and facilitate the management of adverse reactions.
